世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

インスリン グラルジンの世界市場の洞察、2028年までの予測


Global Insulin Glargine Market Insights, Forecast to 2028

インスリングラルギンは、ランタスなどの名称で販売されている長時間作用型の基礎インスリンアナログ製剤で、1日1回の投与により糖尿病患者の血糖値のコントロールをサポートします。本剤は、インスリンを徐放す... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2022年4月15日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

インスリングラルギンは、ランタスなどの名称で販売されている長時間作用型の基礎インスリンアナログ製剤で、1日1回の投与により糖尿病患者の血糖値のコントロールをサポートします。本剤は、インスリンを徐放する微結晶からなり、18~26時間の長い作用時間を有し、「ピークレス」プロファイルを示します(インスリン グラルギンの添付文書による)。

市場の分析と洞察インスリングラルギンの世界市場
COVID-19の大流行により、インスリングラルギンの世界市場規模は2022年に6億7000万米ドル相当と推定され、レビュー期間中にCAGR4.0%で2028年までに8億4880万米ドルに再調整されると予測されています。この健康危機による経済変化を十分に考慮し、2021年にインスリン・グラルギン世界市場の%を占めたPrefilled Injectionは、2028年までに100万米ドルの価値を持ち、ポストCOVID-19期間に修正された%のCAGRで成長すると予測されます。一方、1型糖尿病治療セグメントは、この予測期間を通して%CAGRに変更されています。

世界のインスリン グラルギンの主要なプレーヤーは、Sanofi、Eli Lillyなどです。世界の上位2社で50%近いシェアを占めています。
米国が最大の市場であり、60%以上のシェアを占め、中国、欧州がそれに続き、いずれも35%程度のシェアを有しています。
製品別では、プレフィルドシリンジが最大のセグメントで、約75%のシェアを持っています。また、用途別では、2型糖尿病の治療薬が最も多く、次いで1型糖尿病の治療薬となっています。

インスリン グラルジンの世界的な範囲とセグメント
インスリン グラルギン市場は、タイプ別とアプリケーション別に分類されます。世界のインスリン グラルギン市場のプレイヤー、ステークホルダー、その他の参加者は、このレポートを強力なリソースとして利用することで、優位に立つことができるようになることでしょう。セグメント別分析では、2017年から2028年までのタイプ別およびアプリケーション別の売上、収益、予測に焦点を当てています。

タイプ別セグメント
プレフィルドインジェクション
ノンプレフィルドインジェクション

用途別セグメント
1型糖尿病治療薬
2型糖尿病治療剤

会社別
サノフィ
Eli Lilly
ビアトリス
ガン&リー・ファーマシューティカルズ
東華東方製薬
ユナイテッド・ラボラトリーズ・インターナショナル

地域別
北アメリカ
米国
カナダ
欧州
ドイツ
フランス
英国
イタリア
ロシア
アジア太平洋地域
中国
日本
韓国
インド
オーストラリア
中国 台湾
インドネシア
タイ
マレーシア
中南米
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
UAE


ページTOPに戻る


目次

1 Study Coverage
1.1 Insulin Glargine Product Introduction
1.2 Market by Type
1.2.1 Global Insulin Glargine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Prefilled Injection
1.2.3 Non-Prefilled Injection
1.3 Market by Application
1.3.1 Global Insulin Glargine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Type 1 Diabetes Treatment
1.3.3 Type 2 Diabetes Treatment
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Insulin Glargine Sales Estimates and Forecasts 2017-2028
2.2 Global Insulin Glargine Revenue Estimates and Forecasts 2017-2028
2.3 Global Insulin Glargine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Insulin Glargine Sales by Region
2.4.1 Global Insulin Glargine Sales by Region (2017-2022)
2.4.2 Global Sales Insulin Glargine by Region (2023-2028)
2.5 Global Insulin Glargine Revenue by Region
2.5.1 Global Insulin Glargine Revenue by Region (2017-2022)
2.5.2 Global Insulin Glargine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Insulin Glargine Sales by Manufacturers
3.1.1 Global Top Insulin Glargine Manufacturers by Sales (2017-2022)
3.1.2 Global Insulin Glargine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Insulin Glargine in 2021
3.2 Global Insulin Glargine Revenue by Manufacturers
3.2.1 Global Insulin Glargine Revenue by Manufacturers (2017-2022)
3.2.2 Global Insulin Glargine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Insulin Glargine Revenue in 2021
3.3 Global Insulin Glargine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Insulin Glargine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Insulin Glargine Sales by Type
4.1.1 Global Insulin Glargine Historical Sales by Type (2017-2022)
4.1.2 Global Insulin Glargine Forecasted Sales by Type (2023-2028)
4.1.3 Global Insulin Glargine Sales Market Share by Type (2017-2028)
4.2 Global Insulin Glargine Revenue by Type
4.2.1 Global Insulin Glargine Historical Revenue by Type (2017-2022)
4.2.2 Global Insulin Glargine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Insulin Glargine Revenue Market Share by Type (2017-2028)
4.3 Global Insulin Glargine Price by Type
4.3.1 Global Insulin Glargine Price by Type (2017-2022)
4.3.2 Global Insulin Glargine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Insulin Glargine Sales by Application
5.1.1 Global Insulin Glargine Historical Sales by Application (2017-2022)
5.1.2 Global Insulin Glargine Forecasted Sales by Application (2023-2028)
5.1.3 Global Insulin Glargine Sales Market Share by Application (2017-2028)
5.2 Global Insulin Glargine Revenue by Application
5.2.1 Global Insulin Glargine Historical Revenue by Application (2017-2022)
5.2.2 Global Insulin Glargine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Insulin Glargine Revenue Market Share by Application (2017-2028)
5.3 Global Insulin Glargine Price by Application
5.3.1 Global Insulin Glargine Price by Application (2017-2022)
5.3.2 Global Insulin Glargine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Insulin Glargine Market Size by Type
6.1.1 North America Insulin Glargine Sales by Type (2017-2028)
6.1.2 North America Insulin Glargine Revenue by Type (2017-2028)
6.2 North America Insulin Glargine Market Size by Application
6.2.1 North America Insulin Glargine Sales by Application (2017-2028)
6.2.2 North America Insulin Glargine Revenue by Application (2017-2028)
6.3 North America Insulin Glargine Market Size by Country
6.3.1 North America Insulin Glargine Sales by Country (2017-2028)
6.3.2 North America Insulin Glargine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Insulin Glargine Market Size by Type
7.1.1 Europe Insulin Glargine Sales by Type (2017-2028)
7.1.2 Europe Insulin Glargine Revenue by Type (2017-2028)
7.2 Europe Insulin Glargine Market Size by Application
7.2.1 Europe Insulin Glargine Sales by Application (2017-2028)
7.2.2 Europe Insulin Glargine Revenue by Application (2017-2028)
7.3 Europe Insulin Glargine Market Size by Country
7.3.1 Europe Insulin Glargine Sales by Country (2017-2028)
7.3.2 Europe Insulin Glargine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Insulin Glargine Market Size by Type
8.1.1 Asia Pacific Insulin Glargine Sales by Type (2017-2028)
8.1.2 Asia Pacific Insulin Glargine Revenue by Type (2017-2028)
8.2 Asia Pacific Insulin Glargine Market Size by Application
8.2.1 Asia Pacific Insulin Glargine Sales by Application (2017-2028)
8.2.2 Asia Pacific Insulin Glargine Revenue by Application (2017-2028)
8.3 Asia Pacific Insulin Glargine Market Size by Region
8.3.1 Asia Pacific Insulin Glargine Sales by Region (2017-2028)
8.3.2 Asia Pacific Insulin Glargine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Insulin Glargine Market Size by Type
9.1.1 Latin America Insulin Glargine Sales by Type (2017-2028)
9.1.2 Latin America Insulin Glargine Revenue by Type (2017-2028)
9.2 Latin America Insulin Glargine Market Size by Application
9.2.1 Latin America Insulin Glargine Sales by Application (2017-2028)
9.2.2 Latin America Insulin Glargine Revenue by Application (2017-2028)
9.3 Latin America Insulin Glargine Market Size by Country
9.3.1 Latin America Insulin Glargine Sales by Country (2017-2028)
9.3.2 Latin America Insulin Glargine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Insulin Glargine Market Size by Type
10.1.1 Middle East and Africa Insulin Glargine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Insulin Glargine Revenue by Type (2017-2028)
10.2 Middle East and Africa Insulin Glargine Market Size by Application
10.2.1 Middle East and Africa Insulin Glargine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Insulin Glargine Revenue by Application (2017-2028)
10.3 Middle East and Africa Insulin Glargine Market Size by Country
10.3.1 Middle East and Africa Insulin Glargine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Insulin Glargine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Overview
11.1.3 Sanofi Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Overview
11.2.3 Eli Lilly Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Eli Lilly Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eli Lilly Recent Developments
11.3 Viatris
11.3.1 Viatris Corporation Information
11.3.2 Viatris Overview
11.3.3 Viatris Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Viatris Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Viatris Recent Developments
11.4 Gan&Lee Pharmaceuticals
11.4.1 Gan&Lee Pharmaceuticals Corporation Information
11.4.2 Gan&Lee Pharmaceuticals Overview
11.4.3 Gan&Lee Pharmaceuticals Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Gan&Lee Pharmaceuticals Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Gan&Lee Pharmaceuticals Recent Developments
11.5 Tonghua Dongbao Pharmaceutical
11.5.1 Tonghua Dongbao Pharmaceutical Corporation Information
11.5.2 Tonghua Dongbao Pharmaceutical Overview
11.5.3 Tonghua Dongbao Pharmaceutical Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Tonghua Dongbao Pharmaceutical Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
11.6 United Laboratories International
11.6.1 United Laboratories International Corporation Information
11.6.2 United Laboratories International Overview
11.6.3 United Laboratories International Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 United Laboratories International Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 United Laboratories International Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Insulin Glargine Industry Chain Analysis
12.2 Insulin Glargine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Insulin Glargine Production Mode & Process
12.4 Insulin Glargine Sales and Marketing
12.4.1 Insulin Glargine Sales Channels
12.4.2 Insulin Glargine Distributors
12.5 Insulin Glargine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Insulin Glargine Industry Trends
13.2 Insulin Glargine Market Drivers
13.3 Insulin Glargine Market Challenges
13.4 Insulin Glargine Market Restraints
14 Key Findings in The Global Insulin Glargine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

 

ページTOPに戻る


 

Summary

nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).

Market Analysis and Insights: Global Insulin Glargine Market
Due to the COVID-19 pandemic, the global Insulin Glargine market size is estimated to be worth US$ 6708 million in 2022 and is forecast to a readjusted size of US$ 8487.8 million by 2028 with a CAGR of 4.0% during the review period. Fully considering the economic change by this health crisis, Prefilled Injection accounting for % of the Insulin Glargine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Type 1 Diabetes Treatment segment is altered to an % CAGR throughout this forecast period.

Global Insulin Glargine key players include Sanofi, Eli Lilly, etc. Global top two manufacturers hold a share nearly 50%.
USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.
In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.

Global Insulin Glargine Scope and Segment
Insulin Glargine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Insulin Glargine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type
Prefilled Injection
Non-Prefilled Injection

Segment by Application
Type 1 Diabetes Treatment
Type 2 Diabetes Treatment

By Company
Sanofi
Eli Lilly
Viatris
Gan&Lee Pharmaceuticals
Tonghua Dongbao Pharmaceutical
United Laboratories International

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE



ページTOPに戻る


Table of Contents

1 Study Coverage
1.1 Insulin Glargine Product Introduction
1.2 Market by Type
1.2.1 Global Insulin Glargine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Prefilled Injection
1.2.3 Non-Prefilled Injection
1.3 Market by Application
1.3.1 Global Insulin Glargine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Type 1 Diabetes Treatment
1.3.3 Type 2 Diabetes Treatment
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Insulin Glargine Sales Estimates and Forecasts 2017-2028
2.2 Global Insulin Glargine Revenue Estimates and Forecasts 2017-2028
2.3 Global Insulin Glargine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Insulin Glargine Sales by Region
2.4.1 Global Insulin Glargine Sales by Region (2017-2022)
2.4.2 Global Sales Insulin Glargine by Region (2023-2028)
2.5 Global Insulin Glargine Revenue by Region
2.5.1 Global Insulin Glargine Revenue by Region (2017-2022)
2.5.2 Global Insulin Glargine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Insulin Glargine Sales by Manufacturers
3.1.1 Global Top Insulin Glargine Manufacturers by Sales (2017-2022)
3.1.2 Global Insulin Glargine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Insulin Glargine in 2021
3.2 Global Insulin Glargine Revenue by Manufacturers
3.2.1 Global Insulin Glargine Revenue by Manufacturers (2017-2022)
3.2.2 Global Insulin Glargine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Insulin Glargine Revenue in 2021
3.3 Global Insulin Glargine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Insulin Glargine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Insulin Glargine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Insulin Glargine Sales by Type
4.1.1 Global Insulin Glargine Historical Sales by Type (2017-2022)
4.1.2 Global Insulin Glargine Forecasted Sales by Type (2023-2028)
4.1.3 Global Insulin Glargine Sales Market Share by Type (2017-2028)
4.2 Global Insulin Glargine Revenue by Type
4.2.1 Global Insulin Glargine Historical Revenue by Type (2017-2022)
4.2.2 Global Insulin Glargine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Insulin Glargine Revenue Market Share by Type (2017-2028)
4.3 Global Insulin Glargine Price by Type
4.3.1 Global Insulin Glargine Price by Type (2017-2022)
4.3.2 Global Insulin Glargine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Insulin Glargine Sales by Application
5.1.1 Global Insulin Glargine Historical Sales by Application (2017-2022)
5.1.2 Global Insulin Glargine Forecasted Sales by Application (2023-2028)
5.1.3 Global Insulin Glargine Sales Market Share by Application (2017-2028)
5.2 Global Insulin Glargine Revenue by Application
5.2.1 Global Insulin Glargine Historical Revenue by Application (2017-2022)
5.2.2 Global Insulin Glargine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Insulin Glargine Revenue Market Share by Application (2017-2028)
5.3 Global Insulin Glargine Price by Application
5.3.1 Global Insulin Glargine Price by Application (2017-2022)
5.3.2 Global Insulin Glargine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Insulin Glargine Market Size by Type
6.1.1 North America Insulin Glargine Sales by Type (2017-2028)
6.1.2 North America Insulin Glargine Revenue by Type (2017-2028)
6.2 North America Insulin Glargine Market Size by Application
6.2.1 North America Insulin Glargine Sales by Application (2017-2028)
6.2.2 North America Insulin Glargine Revenue by Application (2017-2028)
6.3 North America Insulin Glargine Market Size by Country
6.3.1 North America Insulin Glargine Sales by Country (2017-2028)
6.3.2 North America Insulin Glargine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Insulin Glargine Market Size by Type
7.1.1 Europe Insulin Glargine Sales by Type (2017-2028)
7.1.2 Europe Insulin Glargine Revenue by Type (2017-2028)
7.2 Europe Insulin Glargine Market Size by Application
7.2.1 Europe Insulin Glargine Sales by Application (2017-2028)
7.2.2 Europe Insulin Glargine Revenue by Application (2017-2028)
7.3 Europe Insulin Glargine Market Size by Country
7.3.1 Europe Insulin Glargine Sales by Country (2017-2028)
7.3.2 Europe Insulin Glargine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Insulin Glargine Market Size by Type
8.1.1 Asia Pacific Insulin Glargine Sales by Type (2017-2028)
8.1.2 Asia Pacific Insulin Glargine Revenue by Type (2017-2028)
8.2 Asia Pacific Insulin Glargine Market Size by Application
8.2.1 Asia Pacific Insulin Glargine Sales by Application (2017-2028)
8.2.2 Asia Pacific Insulin Glargine Revenue by Application (2017-2028)
8.3 Asia Pacific Insulin Glargine Market Size by Region
8.3.1 Asia Pacific Insulin Glargine Sales by Region (2017-2028)
8.3.2 Asia Pacific Insulin Glargine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Insulin Glargine Market Size by Type
9.1.1 Latin America Insulin Glargine Sales by Type (2017-2028)
9.1.2 Latin America Insulin Glargine Revenue by Type (2017-2028)
9.2 Latin America Insulin Glargine Market Size by Application
9.2.1 Latin America Insulin Glargine Sales by Application (2017-2028)
9.2.2 Latin America Insulin Glargine Revenue by Application (2017-2028)
9.3 Latin America Insulin Glargine Market Size by Country
9.3.1 Latin America Insulin Glargine Sales by Country (2017-2028)
9.3.2 Latin America Insulin Glargine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Insulin Glargine Market Size by Type
10.1.1 Middle East and Africa Insulin Glargine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Insulin Glargine Revenue by Type (2017-2028)
10.2 Middle East and Africa Insulin Glargine Market Size by Application
10.2.1 Middle East and Africa Insulin Glargine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Insulin Glargine Revenue by Application (2017-2028)
10.3 Middle East and Africa Insulin Glargine Market Size by Country
10.3.1 Middle East and Africa Insulin Glargine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Insulin Glargine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Sanofi
11.1.1 Sanofi Corporation Information
11.1.2 Sanofi Overview
11.1.3 Sanofi Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Sanofi Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Overview
11.2.3 Eli Lilly Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Eli Lilly Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eli Lilly Recent Developments
11.3 Viatris
11.3.1 Viatris Corporation Information
11.3.2 Viatris Overview
11.3.3 Viatris Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Viatris Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Viatris Recent Developments
11.4 Gan&Lee Pharmaceuticals
11.4.1 Gan&Lee Pharmaceuticals Corporation Information
11.4.2 Gan&Lee Pharmaceuticals Overview
11.4.3 Gan&Lee Pharmaceuticals Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Gan&Lee Pharmaceuticals Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Gan&Lee Pharmaceuticals Recent Developments
11.5 Tonghua Dongbao Pharmaceutical
11.5.1 Tonghua Dongbao Pharmaceutical Corporation Information
11.5.2 Tonghua Dongbao Pharmaceutical Overview
11.5.3 Tonghua Dongbao Pharmaceutical Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Tonghua Dongbao Pharmaceutical Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
11.6 United Laboratories International
11.6.1 United Laboratories International Corporation Information
11.6.2 United Laboratories International Overview
11.6.3 United Laboratories International Insulin Glargine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 United Laboratories International Insulin Glargine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 United Laboratories International Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Insulin Glargine Industry Chain Analysis
12.2 Insulin Glargine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Insulin Glargine Production Mode & Process
12.4 Insulin Glargine Sales and Marketing
12.4.1 Insulin Glargine Sales Channels
12.4.2 Insulin Glargine Distributors
12.5 Insulin Glargine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Insulin Glargine Industry Trends
13.2 Insulin Glargine Market Drivers
13.3 Insulin Glargine Market Challenges
13.4 Insulin Glargine Market Restraints
14 Key Findings in The Global Insulin Glargine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る